Unveiling the Complexities of Hereditary Angioedema
Authors:
- Cristina Violeta TutunaruCTCristina Violeta Tutunaru
- Oana Maria IcăOIOana Maria Ică
- George G. MitroiGMGeorge G. Mitroi
- Carmen Daniela NeagoeCNCarmen Daniela Neagoe
- George F. MitroiGMGeorge F. Mitroi
- Olguța Anca OrzanOlguța Anca Orzan
- Beatrice Bălăceanu-GurăuBeatrice Bălăceanu-Gurău
- Simona Laura IanoșiSimona Laura Ianoși
Open Access
- 14 October 2024
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 14 (10) , 1298
Abstract
Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder, constituting approximately 2% of all clinical cases of angioedema, with a global prevalence estimated between 1 in 50,000 and 1 in 150,000 individuals. The condition affects individuals of all genders and ethnic backgrounds without significant variation. HAE is classified into three types. Type I HAE, which accounts for 85% of cases, is characterized by a deficiency of the C1 esterase inhibitor (C1-INH) gene. Type II HAE, making up 15% of cases, involves a dysfunctional C1-INH. Type III HAE, which represents about 5% to 10% of cases, is often estrogen-dependent and although several mutations have been identified, it typically involves normal C1-INH activity. Despite the differences in C1-INH functionality, all three types of HAE manifest with similar clinical symptoms. HAE leads to recurrent episodes of non-pruritic angioedema, which occurs in the absence of urticaria. Breakthroughs in understanding HAE pathophysiology have revolutionized treatment, leading to the development of highly targeted therapies for both acute management and long-term prevention. Meanwhile, cutting-edge advancements in omics technologies are unlocking new possibilities for biomarker discovery, paving the way for more precise diagnoses and personalized treatment strategies that could significantly enhance patient outcomes. This review will delve into the intricate pathophysiology, diverse clinical presentations, and diagnostic challenges of HAE while exploring emerging biomarkers and innovative approaches to therapeutic management and prevention strategies. Additionally, it will underscore the vital importance of screening family members of affected individuals, even when symptoms are not present.Keywords
Funding Information
- University of Medicine and Pharmacy of Craiova, Romania
This publication has 126 references indexed in Scilit:
- Interventions for the long-term prevention of hereditary angioedema attacksCochrane Database of Systematic Reviews, 2019
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema AttacksJAMA, 2018
- The use of tranexamic acid for on‐demand and prophylactic treatment of hereditary angioedema—A systematic reviewJournal of Cutaneous Immunology and Allergy, 2018
- Training patients for self‐administration of a new subcutaneous C1‐inhibitor concentrate for hereditary angioedemaNursing Open, 2018
- Genetics of Hereditary Angioedema RevisitedClinical Reviews in Allergy & Immunology, 2016
- Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1Journal of Clinical Immunology, 2016
- Growth factors and IL-17 in hereditary angioedemaClinical and Experimental Medicine, 2015
- Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System DatabasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- Endothelial Cell Function in Patients with Hereditary Angioedema: Elevated Soluble E-selectin Level During Inter-attack PeriodsJournal of Clinical Immunology, 2011
- Hereditary AngioedemaArchives of internal medicine (1960), 2001